Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Firdapse® (amifampridine) – Updated dosing
May 30, 2024 - The FDA approved updated dosing for Catalyst Pharmaceuticals’ Firdapse (amifampridine), for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults and pediatric patients 6 years of age and older.
